Literature DB >> 20493788

[Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology.].

C Medrano López1, L García-Guereta, L Fernández Pineda, P Malo Concepción, E Maroto Alvaro, J Santos de Soto, J Lirio Casero, P Suárez Cabrera, F Caballero Martínez.   

Abstract

BACKGROUND: Following the results of the CIVIC study, the SECPCC proposes to revise its recommendations for the prevention of RSV, taking into account the new evidence, as well as the preventive experience of paediatric cardiologists. For this purpose a structured method of professional consensus has been chosen.
OBJECTIVES: To develop a Spanish clinical consensus on preventing infection by RSV under the auspices of the Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas.
METHODS: Delphi Consensus modified in two rounds. The study was conducted in four phases: 1) constitution of a Scientific Committee for bibliographic review and submission of the recommendations for discussion, 2) constitution of an Expert Panel with 75 representatives in the speciality, 3) postal survey organised in two rounds and intermediate processing of opinions, and issuing of a report to the panellists, and 4) discussion of the results in a face-to-face meeting of the Scientific Committee.
RESULTS: Consensus was reached on 54 of the 70 preventive recommendations analysed. With respect to the 16 remaining issues, no consensus was reached, due to differences in professional opinion and the absence of established criteria among the majority of the experts.
CONCLUSIONS: A set of recommendations for RSV prophylaxis in cardiology was developed and updated, rated in accordance with the degree of professional consensus on which they were based. These can be considered valid until such time as new scientific information emerges that warrants a further review. Copyright 2009 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20493788     DOI: 10.1016/j.anpedi.2010.03.001

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  1 in total

1.  Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.

Authors:  Ralph Schmidt; Istvan Majer; Natalia García Román; Alejandra Rivas Basterra; ElizaBeth Grubb; Constancio Medrano López
Journal:  Health Econ Rev       Date:  2017-12-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.